Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

5 PARP-Related Questions for Melinda L. Telli, MD

August 2nd 2012

Melinda L. Telli, MD, is actively involved in clinical research that focuses on DNA repair targeted therapeutics for the treatment of triple-negative and BRCA1/2 mutation-associated breast cancer.

Dr. Gralow Discusses T-DM1-Induced Thrombocytopenia

July 31st 2012

Dr. Julie Gralow from the Seattle Cancer Care Alliance Discusses T-DM1-Induced Thrombocytopenia

Putting Key Developments in Two Tumor Types in Focus

July 27th 2012

As the molecular understanding of breast cancer continues to evolve, the search for treatment targets based upon tumor subtypes and gene expression patterns is intensifying.

Lapatinib Equivalent to Trastuzumab as Neoadjuvant Therapy, but Less Effective in Metastatic Setting

July 24th 2012

Two phase III studies presented at ASCO 2012 explored the role of lapatinib in the treatment of HER2-positive breast cancer.

FDA Approves Everolimus for Advanced Breast Cancer

July 23rd 2012

The FDA has approved everolimus for treating patients with hormone receptor-positive, HER2 negative breast cancer, when given in combination with the aromatase inhibitor exemestane.

Long-Term Hormonal Therapy May Pose Breast Cancer Risk

July 19th 2012

The long-standing debate about postmenopausal hormones and breast cancer gained more evidence to support an increased cancer risk.

Maintaining a Stable Weight May Help Breast Cancer Survivors Avoid Hot Flashes

July 4th 2012

Women who have been previously treated for early-stage breast cancer are much less likely to complain of hot flashes if they remain within 10% of their prediagnosis weight.

Breast Cancer Survival Rises With Cruciferous Vegetable Intake

July 2nd 2012

Breast cancer survival improved significantly in patients who increased consumption of cruciferous vegetables following diagnosis, a study of Chinese women showed.

High Points and Hurdles: Immunotherapy Moves Forward

June 27th 2012

Immunotherapy is maintaining its momentum in clinical development programs, with explorations under way in many tumor types, including breast and lung cancers previously considered poor candidates for such modalities.

Dr. Blackwell Discusses the T-DM1 EMILIA Trial Endpoints

June 26th 2012

Dr. Kimberly Blackwell, from the Duke Cancer Institute, Discusses the T-DM1 EMILIA Trial Coprimary Endpoints

Breast Cancer Risk May Be Linked to Injectable Contraceptive Use

June 23rd 2012

Young women who have recently used DMPA for at least 1 year have more than twice the risk of invasive breast cancer as young women who do not report recent use of the injectable contraceptive.

Breast Cancer and Early-Onset Menopause

June 14th 2012

Whether surgically or medically induced, early menopause forces women to deal with a host of emotional, physical, and practical issues.

Pertuzumab Gains Approval as Dual Anti-HER2 Breast Cancer Treatment

June 11th 2012

The FDA has approved pertuzumab combined with trastuzumab and docetaxel for patients who have not received prior treatment for HER2-positive metastatic breast cancer.

Dr. Baselga on Combining Pertuzumab with Trastuzumab

June 8th 2012

Dr. Wood on Family Histories and Genetic Counseling

June 5th 2012

Dr. Marie Wood, from the University of Vermont, on Family Histories and Genetic Counseling for Breast and Colorectal Cancers.

Two Newer Breast Cancer Therapies Not Superior to Standard Paclitaxel, Study Suggests

June 5th 2012

The newer and more expensive breast cancer treatments nab-paclitaxel and ixabepilone, failed to demonstrate superior efficacy versus standard care with weekly paclitaxel.

Pilot Study Evaluates a Proposed Quality Measure for Family History Collection and Genetic Testing Referral

June 5th 2012

Only half of those with breast cancer and one-quarter of those with colon cancer were referred for genetic counseling or testing by their physicians.

Dr. Rugo on Paclitaxel Superiority in Advanced Breast Cancer

June 5th 2012

Dr. Hope Rugo, from the UCSK Comprehensive Cancer Center, on the First-line Superiority of Paclitaxel for Advanced Breast Cancer.

Dr. Blackwell Discusses the T-DM1 EMILIA Trial

June 3rd 2012

Dr. Kimberly Blackwell, from the Duke Cancer Institute, Discusses the T-DM1 EMILIA Trial

Antibody Drug Conjugate T-DM1 Improves PFS in HER2-Positive Breast Cancer

June 3rd 2012

T-DM1 extended progression-free survival by 3.2 months in women with HER2-positive locally advanced or metastatic breast cancer.